Galderma, a global specialty pharmaceutical company focused on dermatology, has announced a positive outcome of the European Decentralised Procedure (DCP)...
Galderma Laboratories, L.P. has announced on 24 December 2014 the FDA approved Soolantra (ivermectin) Cream, 1% for the once-daily topical...
Soolantra is indicated for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.
Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Galderma announced that the FDA approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Trifarotene is the first...
Arcutis Biotherapeutics, Inc. announced that it has commenced pivotal Phase III clinical trials evaluating topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis (AD).
Background: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.
Dipexium Pharmaceuticals, Inc. announced that the OneStep-1 and OneStep-2 Phase III clinical trials of Locilex (pexiganan cream 0.8%) in patients...